Clinical Trial Detail

NCT ID NCT01865747
Title A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements no
Sponsors Exelixis
Indications

renal cell carcinoma

Therapies

Everolimus

Cabozantinib

Age Groups: adult senior

No variant requirements are available.